Campbell & CO Investment Adviser LLC Trims Stock Holdings in Encompass Health Corporation $EHC

Campbell & CO Investment Adviser LLC lowered its position in shares of Encompass Health Corporation (NYSE:EHC) by 43.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 13,311 shares of the company’s stock after selling 10,126 shares during the quarter. Campbell & CO Investment Adviser LLC’s holdings in Encompass Health were worth $1,691,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Tectonic Advisors LLC boosted its stake in Encompass Health by 1.6% during the third quarter. Tectonic Advisors LLC now owns 5,337 shares of the company’s stock worth $678,000 after acquiring an additional 82 shares in the last quarter. Global Retirement Partners LLC lifted its holdings in shares of Encompass Health by 23.0% during the third quarter. Global Retirement Partners LLC now owns 449 shares of the company’s stock valued at $57,000 after purchasing an additional 84 shares during the last quarter. EP Wealth Advisors LLC boosted its position in shares of Encompass Health by 2.4% in the 2nd quarter. EP Wealth Advisors LLC now owns 3,694 shares of the company’s stock worth $453,000 after purchasing an additional 88 shares in the last quarter. Natural Investments LLC grew its stake in shares of Encompass Health by 1.2% in the 3rd quarter. Natural Investments LLC now owns 7,808 shares of the company’s stock worth $991,000 after buying an additional 89 shares during the last quarter. Finally, TD Private Client Wealth LLC increased its position in Encompass Health by 1.1% during the 3rd quarter. TD Private Client Wealth LLC now owns 8,216 shares of the company’s stock valued at $1,044,000 after buying an additional 91 shares in the last quarter. 97.25% of the stock is owned by hedge funds and other institutional investors.

Encompass Health Stock Down 2.2%

Shares of Encompass Health stock opened at $100.49 on Friday. Encompass Health Corporation has a twelve month low of $92.53 and a twelve month high of $127.99. The company has a quick ratio of 1.14, a current ratio of 1.14 and a debt-to-equity ratio of 0.76. The company’s 50 day moving average is $109.34 and its 200 day moving average is $116.29. The company has a market cap of $10.11 billion, a price-to-earnings ratio of 19.00, a price-to-earnings-growth ratio of 1.62 and a beta of 0.74.

Encompass Health (NYSE:EHC) last posted its earnings results on Wednesday, October 29th. The company reported $1.23 EPS for the quarter, topping analysts’ consensus estimates of $1.19 by $0.04. The business had revenue of $1.48 billion during the quarter, compared to the consensus estimate of $1.48 billion. Encompass Health had a net margin of 9.33% and a return on equity of 17.84%. The firm’s revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.03 EPS. Research analysts anticipate that Encompass Health Corporation will post 4.8 EPS for the current year.

Encompass Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, January 15th. Shareholders of record on Friday, January 2nd were given a $0.19 dividend. This represents a $0.76 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend was Friday, January 2nd. Encompass Health’s dividend payout ratio (DPR) is presently 14.37%.

Analysts Set New Price Targets

Several equities research analysts have commented on EHC shares. Zacks Research downgraded Encompass Health from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 19th. Weiss Ratings reissued a “buy (b+)” rating on shares of Encompass Health in a research report on Wednesday, October 8th. Raymond James Financial raised shares of Encompass Health to a “strong-buy” rating in a report on Friday, October 31st. Wall Street Zen upgraded shares of Encompass Health from a “hold” rating to a “buy” rating in a report on Sunday. Finally, UBS Group upped their price objective on Encompass Health from $140.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, October 2nd. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $142.86.

Encompass Health Company Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.